GlassScriptPhysician profile
Anthony T Brand
NPI 1851730931
$4,915.40
in general payments reported to CMS, 2019-2025
34 companies · $822 in 2025
The $822 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $301 · 2021: $512 · 2022: $484 · 2023: $1,177 · 2024: $1,137 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,134.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $511.95 | 2019-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $510.97 | 2021-2025 | Acthar |
| Bausch & Lomb Americas INC. | $392.43 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Novartis Pharmaceuticals Corporation | $365.12 | 2019-2023 | |
| Glaukos Corporation | $336.42 | 2021-2025 | Idose, Photrexa Cross-Linking Kit, Ce-Marked Kxla System |
| Abbvie INC. | $271.76 | 2022-2024 | Durysta, Ozurdex |
| Oyster Point Pharma, INC. | $268.62 | 2022-2025 | Tyrvaya |
| Dompe US, INC. | $254.02 | 2022-2025 | Oxervate |
| Alcon Vision LLC | $251.74 | 2019-2025 | Rocklatan, Clareon |
| Allergan, INC. | $202.90 | 2019-2021 | |
| Sight Sciences, INC. | $162.73 | 2021-2023 | Omni Surgical System |
| Rxsight INC | $125.93 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $111.75 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $109.34 | 2019-2021 | |
| Genentech USA, INC. | $102.87 | 2023-2025 | Vabysmo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $97.04 | 2024 | Cimerli |
| Biotissue Holdings INC. | $93.19 | 2024-2025 | |
| Coherus Oncology, INC. | $84.40 | 2023-2024 | |
| Tarsus Pharmaceuticals, INC. | $82.11 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $78.73 | 2023-2024 | Iheezo |
| Ani Pharmaceuticals, INC. | $76.78 | 2024-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Apellis Pharmaceuticals, INC. | $68.09 | 2024-2025 | Syfovre |
| Biogen, INC. | $49.67 | 2023 | |
| Thea Pharma INC. | $48.02 | 2022-2023 | Iyuzeh |
| Regeneron Healthcare Solutions, INC. | $46.61 | 2019-2024 | Eylea |
| Astellas Pharma US INC | $42.62 | 2023-2024 | Izervay |
| Shire North American Group INC | $28.13 | 2019 | |
| Alimera Sciences, INC. | $24.76 | 2024 | Yutiq, Iluvien |
| Notal Vision, INC. | $23.49 | 2025 | Foresee Home |
| Genzyme Corporation | $23.27 | 2023 | |
| Amgen INC. | $20.74 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $18.56 | 2020 | |
| Aerie Pharmaceuticals, INC. | $16.99 | 2020 | |
| Eyepoint US, INC. | $13.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Brand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.